MobiHealth News August 25, 2025
British Growth Fund’s exit marks one of the largest for a UK medtech company and the most profitable return in the firm’s history.
British Growth Fund (BGF), a UK- and Ireland-based growth capital investor, has successfully exited Oxford University spinout OrganOx, a medtech company that develops a liver preservation device, in a transaction valued at around $1.5 billion, making it one of the largest-ever exits for a UK medtech company.
BGF said in a statement that the transaction marks the biggest financial return to date for the investment firm, generating £175 million (more than $204.1 million) in proceeds. That equates to a 10x return on investment and an internal rate of return of approximately 69%.
According to the company,...
Today's Sponsors
Today's Sponsor